Library / Regulatory / State map / North Carolina
NC · State regulatory reference

North Carolina.

Moderate

Telemedicine prescribing is governed by NC Medical Board Position Statement 5.1.4 (adopted 2010, amended March 2024), which applies an ordinary standard-of-care framework rather than distinctive restrictions and allows a new relationship to form by synchronous or asynchronous telemedicine with no required prior in-person visit. Compounding under 21 NCAC 46 .1810 and the Board of Pharmacy incorporates USP <795>/<797>. No North Carolina-specific enforcement targeting peptides or compounded GLP-1s was found.

Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
Position Statement 5.1.4 permits establishing a licensee-patient relationship via synchronous or asynchronous telemedicine without a prior in-person meeting so long as the standard of care is met; treatment based solely on a static online questionnaire is not acceptable.
Compounding
21 NCAC 46 .1810 plus the Board of Pharmacy's incorporation of USP <795>/<797> govern non-sterile and sterile compounding, with state additions (USP/NF-grade substances, a practitioner-pharmacist-patient relationship, compounding logs, three-year record retention) — standard 503A oversight.
Sources
  1. 01 NC Medical Board Position Statement 5.1.4 — Telemedicine (adopted 2010, amended Mar. 2024) ↗
  2. 02 NC Board of Pharmacy — General Pharmacy FAQs (USP 795/797/800 incorporation; compounded semaglutide/tirzepatide) ↗
← Back to state map